Key facts
- It has raised $2.6M; the latest was Grant ($1.9M) in Sep 2025.
- Notable investors include Creative Destruction Lab, Artesian, LaunchVic, Breakthrough Victoria, ANDHealth — 14 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 14 names
- ·Watchlist + deal alerts for Diag-Nose.io
- ·The full record, as it builds
Funding rounds
No funding rounds for Diag-Nose.io are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Diag-Nose.io
Operator of a precision medicine platform intended to improve the diagnosis and treatment of chronic nasal disorders. The company combines protein biomarkers, digital biomarkers, and multivariate algorithms to create actionable clinical insights for patients with chronic sinusitis and provides diagnostic clarity around overlapping sinonasal conditions, enabling physicians to administer the appropriate treatment, monitor efficacy, and reduce unnecessary interventions.
- Sector
- Healthcare
- HQ
- Notting Hill, Australia
- Founded
- 2020
- Employees
- 33
- Website
- diag-nose.io/
- Ownership
- Privately Held (backing)
Diag-Nose.io doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Diag-Nose.io shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Diag-Nose.io in its N-PORT filings yet. We sweep new filings monthly.